Skip to content
Subscribe
← Back
trademark

Madras High Court Upholds ‘CORTIL’ Registration for Micro Labs

9 min readUpdated November 6, 2026 Analysis
Madras High Court Upholds ‘CORTIL’ Registration for Micro Labs - Madras High Court

Reading Tools

In CORONA REMEDIES LIMITED Vs MICRO LABS PRIVATE LIMITED [OP(TM).66/2024], the Madras High Court refused to expunge or restrict the long-standing Class 5 trademark registration for “CORTIL” held by Micro Labs Private Limited, dismissing a rectification petition brought by Corona Remedies Limited under Sections 47 and 57 of the Trade Marks Act, 1999. Presiding over the Intellectual Property Division, Hon’ble Mr. Justice K. Kumaresh Babu held that Micro Labs successfully defeated allegations of non-use by establishing continuous, unbroken commercial sales from 2005 through 2025 via documented tax invoices, thereby affirming that statutory exclusivity under Section 28 cannot be disturbed when active commercial exploitation across Class 5 is proven.

Disputed Subject MatterRegistered Trademark “CORTIL” (Application No. 416090 in Class 5 covering pharmaceutical and medicinal preparations) versus Junior Mark “CORTEL” (Telmisartan anti-hypertensive formulation).
Plaintiff / Petitioner’s CaseCorona Remedies sought complete expungement or partial specification restriction of “CORTIL” under Sections 47 and 57, alleging non-use for over five years, overbroad specification coverage, and fraudulent misrepresentation of adoption dates.
Defendant / Respondent’s DefenseMicro Labs asserted continuous user since 1976, statutory registration since 1988, unbroken renewals through 2025/2035, and uninterrupted commercial sales substantiated by tax invoices from 2005 to 2025 across multiple product line extensions.
Governing Law & AuthoritiesSections 28, 34, 47, and 57 of the Trade Marks Act, 1999; Vishnudas Trading v. Vazir Sultan Tobacco Co. Ltd. (1997); S. Syed Mohideen v. P. Sulochana Bai (2016); Neon Laboratories v. Medical Technologies (2016).
Decisive Holding & ReliefOriginal Petition dismissed entirely without costs. Rectification refused; Micro Labs retained exclusive registered rights over “CORTIL” across Class 5.

The Class 5 Rectification Contest: Statutory Monopoly vs Non-Use Vulnerability under Sections 47 and 57

Struggling with Indian Trademark Law principles? Explore our complete Trademark Law Guide.

The controversy originated from an intense commercial conflict between two major Indian pharmaceutical manufacturers over confusingly similar brand names in Class 5. Corona Remedies Limited, represented by advocate Mr. Vikas Khera, instituted an original petition before the Madras High Court seeking the rectification of the Trade Marks Register under Sections 47 and 57 of the Trade Marks Act, 1999. The petitioner sought the total expungement of Micro Labs Private Limited’s registered trademark “CORTIL” (registered under Application No. 416090 in Class 5) or, in the alternative, a partial cancellation restricting the registration exclusively to hormone analogues containing carbidopa and levodopa in tablet form.

Corona Remedies contended that it had honestly coined and adopted the trademark “CORTEL” on October 18, 2007, to market Telmisartan, an anti-hypertensive formulation prescribed for cardiovascular conditions. The petitioner explained that “CORTEL” was an invented mark created by combining its corporate prefix “COR” (derived from Corona Remedies) with the suffix “TEL” (derived from the active molecule Telmisartan). Having expanded its market presence, Corona Remedies sought registration for “CORTEL” and its variants under Class 5. However, Micro Labs filed opposition proceedings (Opposition Nos. 749794 and 979561) relying on its senior registration for “CORTIL”. The Registrar of Trademarks refused Corona Remedies’ Application No. 1685329 for “CORTEL 20”, prompting an appeal before the High Court of Gujarat and driving Corona Remedies to initiate this rectification strike in Chennai.

In its petition, Corona Remedies alleged that Micro Labs had committed fraud upon the Trade Marks Registry by declaring conflicting adoption dates. In its original Form TM-1, Micro Labs claimed use from 1976, whereas in opposition pleadings against “CORTEL”, it stated adoption in July 1988. Furthermore, Corona Remedies asserted that Micro Labs registered “CORTIL” across a broad spectrum of “pharmaceutical and medicinal preparations” but actually used the mark for a very narrow range of hormone preparations. Relying on the five-year non-use vulnerability under Section 47, Corona Remedies argued that Micro Labs had abandoned the mark across the broader class, creating defensive deadwood that prejudiced legitimate commercial competitors.

Doctrinal Harmonization: Interplay of Section 28 Rights, Section 34 Savings, and Vishnudas Class-Restriction Principles

The substantive controversy required the court to navigate the statutory friction between the exclusive rights conferred by Section 28 and the remedial mechanisms provided by Sections 47 and 57 of the Act. Section 28 confers exclusive rights upon a registered proprietor to use the trademark in relation to the goods for which it is registered. However, Indian trademark jurisprudence firmly establishes that statutory registration does not create an absolute property right if the mark remains unexploited or if the register is tainted by entries made without sufficient cause.

Corona Remedies placed heavy reliance on the foundational Supreme Court decision in Vishnudas Trading v. Vazir Sultan Tobacco Co. Ltd. (1997) 4 SCC 201, alongside rulings in Suresh Kumar Jain v. Union of India (2012 SCC OnLine Del 12) and Sun Pharma Laboratories Ltd. v. Cian Healthcare Ltd. (2023 SCC OnLine Del 2602). In Vishnudas Trading, the Supreme Court established that a registered proprietor who secures registration for a broad, comprehensive class of goods but confines actual commercial activity to a single sub-category cannot prevent another trader from registering the same mark for a distinct sub-category. Applying this ratio, Corona Remedies argued that Micro Labs could not monopolize the entire Class 5 spectrum to block an anti-hypertensive product when Micro Labs only manufactured synthetic hormone analogues.

Section 47, Trade Marks Act, 1999

Removal from register and imposition of limitations on ground of non-use: A registered trade mark may be taken off the register in respect of any goods or services if registered without any bonafide intention to use, or if there has been no bonafide use thereof for a continuous period of five years and three months prior to the date of application.

However, the High Court recognized that the doctrine of specification restriction under Vishnudas Trading cannot be mechanically applied to the pharmaceutical sector without scrutinizing continuous commercial activity. While common law prior user rights under Section 34 override statutory registrations as affirmed in S. Syed Mohideen v. P. Sulochana Bai (2016) 2 SCC 683, the inverse principle dictates that a registered owner who maintains active, continuous commercial use is fully protected against Section 47 non-use actions. In Neon Laboratories Ltd. v. Medical Technologies Ltd. (2016) 2 SCC 672, the Supreme Court stressed that initial user dates and uninterrupted market exploitation dictate priority. Furthermore, the principles established in Wander Ltd. v. Antox India P. Ltd. (1990) Supp SCC 727 dictate that established commercial use creates substantial equity that courts will not lightly dismantle.

Evaluating the documentary record submitted by Micro Labs, the High Court delivered its factual finding regarding continuous commercial user:

This court further notes that the first respondent at present has been in continuous usage of its impugned trademark “CORTIL” and the same stands substantiated by the copies of tax invoices commencing from 2005 till 2025 found in the typeset filed by the first respondent along with its Counter Statement. Wherein, it can be seen that the various products under different trademarks of the first respondent, including the impugned trademark and its variants, have been dealt with over the years, clearly evincing the first respondent’s continuous use of the impugned trademark.

Hon’ble Mr. Justice K. Kumaresh Babu, Madras High Court

Evidentiary Forensics: Tax Invoice Continuity, CA Certification, and Defeating Overbreadth Allegations

The evidentiary burden in a Section 47 non-use application is exceptionally high. The applicant for rectification must establish two cumulative requirements: either an absence of bona fide intention to use at the time of registration, or an absolute failure to make bona fide commercial use of the mark for a continuous period of five years and three months preceding the petition. Corona Remedies sought to discharge this burden by pointing to statements made by Micro Labs in opposition pleadings and highlighting minor inconsistencies between brand feasibility discussions (1976), first declarations (1979), and statutory grant (1988).

The court’s evidentiary analysis reveals why Micro Labs succeeded where many registered proprietors fail. Micro Labs did not rely on self-serving affidavits or isolated promotional leaflets. Instead, it produced an extensive documentary trail comprising continuous commercial tax invoices spanning two decades, from 2005 through 2025, supported by Chartered Accountant sales certificates. This unbroken commercial record demonstrated that Micro Labs not only actively manufactured and distributed “CORTIL” in tablet form containing Betamethasone IP, but had also launched line extensions including “CORTIL A” and “CORTIL D”.

This continuous commercial exploitation directly defeated the applicability of Vishnudas Trading. Unlike a passive mark owner holding a defensive registration without commercial intent, Micro Labs actively used “CORTIL” within Class 5. The High Court observed that hormones and synthetic analogues fall within the broader description of pharmaceutical and medicinal preparations. Minor historical variations in written pleadings regarding internal feasibility (1976) versus commercial launch (1979/1988) did not constitute deliberate fraud or misrepresentation capable of invalidating a long-standing registration.

Formulating its ratio on the statutory failure of the rectification petition, Justice Kumaresh Babu ruled:

The aforesaid facts do not attract the provisions of Section 47 of the Act and consequently, does not provide any grounds for the rectification of the impugned trademark under Section 57 of the Act. Therefore in view of the above discussion the impugned Trademark of the first respondent “CORTIL” does not warrant any rectification.

Hon’ble Mr. Justice K. Kumaresh Babu, Madras High Court

Dual-Track Strategic Warfare: Opposition Proceedings, Rectification Counter-Strikes, and Order XXXIX Interim Standards

This judgment illustrates the tactical mechanics of dual-track IP litigation in India. When a junior user faces an adverse order in trademark opposition proceedings before the Registry, filing a Section 57 rectification petition before the High Court Intellectual Property Division serves as an aggressive counter-strike designed to eliminate the senior mark or compel a commercial settlement.

In interim injunction battles governed by Order XXXIX Rules 1 and 2 of the Code of Civil Procedure, 1908, courts apply the three-pronged test: prima facie case, balance of convenience, and irreparable injury. Where a senior mark owner demonstrates continuous sales via audited accounts and tax invoices, the balance of convenience sways decisively in favor of preserving the registered entry. In pharmaceutical disputes, courts apply a higher standard of scrutiny because phonetic similarity between competing medicine names creates grave public health risks. The structural substitution of a single letter (“I” in “CORTIL” versus “E” in “CORTEL”) is insufficient to eliminate deceptive similarity when both drugs operate within overlapping clinical environments.

By failing to secure the rectification of “CORTIL”, Corona Remedies remains exposed to infringement actions under Section 29. Furthermore, Corona Remedies’ tactical maneuver of obtaining registrations for “CORTEL” in Classes 29 and 30 (covering food items and processed goods) backfired. The High Court noted that securing registrations in non-pharmaceutical classes for a brand allegedly coined for the Telmisartan antihypertensive molecule reflected poorly on the petitioner’s overall bona fides, underscoring how flawed dual-track strategies can undermine a litigant’s standing across multiple forums.

Key Precedents & Statutory Guidance

Corporate Risk Governance and IP Portfolio Management for In-House Counsel

The dismissal of OP(TM) No. 66 of 2024 offers critical risk management lessons for corporate general counsel and brand managers operating in high-stakes manufacturing sectors:

  • The Registration Illusion in Class 5: In-house counsel must recognize that securing a clean search report in unassigned classes or filing defensive applications in Classes 29 and 30 provides zero immunity against a senior registered proprietor in Class 5. Brand adoption strategies must focus on absolute phonetic and structural dissimilarity rather than minor single-letter variations.
  • Documentary Preservation Protocols: Micro Labs survived a rectification attack precisely because it preserved audited tax invoices spanning 2005 to 2025. Corporate legal departments must implement mandatory digital archiving for batch manufacturing records, GST invoices, shipping bills, and promotional spend logs to defeat Section 47 non-use challenges.
  • Pre-Launch Clearance Forensics: Clearance searches must extend beyond basic exact-match registry queries. Comprehensive due diligence requires phonetic algorithm scraping, state drug authority filing reviews, and physical market surveillance to detect legacy registrations dating back several decades.
  • Strategic Realignment Upon Senior Mark Discovery: When pre-launch clearance reveals a senior registered mark like “CORTIL”, corporate counsel should avoid relying on speculative rectification petitions. The safer commercial path requires early brand redesign, honest concurrent use negotiation, or structured territorial coexistence before sinking substantial capital into market distribution.

Case Details: CORONA REMEDIES LIMITED Vs MICRO LABS PRIVATE LIMITED | Case Number: OP(TM).66/2024 | Court: Madras High Court | Date: 2026-11-04

Presiding Bench: Hon’ble THE HON’BLE MR.JUSTICE K.KUMARESH BABU

Appearances: For Petitioner(s): Mr.Vikas Khera | For Respondent(s): No Appearance

Read the Official Judgment/Order Here

Written by

Adv. Koushik Chittella

IP Law Practitioner

Indian IP Law Trademark Patent Copyright

An Advocate enrolled on the rolls of the Bar Council of the State of Andhra Pradesh. What started as curiosity about how the law protects ideas, brands, inventions, and creative works gradually developed into a genuine passion for studying and explaining IP law, inspiring me to pursue a Masters degree (LL.M.) in Intellectual Property Rights (IPR).